Novel topical esmolol hydrochloride (galnobax) for diabetic foot wound: phase 1/2, multicenter, randomized, double-blind, vehicle-controlled parallel-group study
1. 系统已在2025-04-18 11:36:35对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
A Rastogi, SA Kulkarni, SK Deshpande…
Advances in Wound …, 2023
liebertpub.com
We aimed to assess safety and dose-finding efficacy of esmolol hydrochloride (Galnobax) for healing of diabetic foot ulcer (DFU). This is phase 1/2 multicenter, randomized, double-blind vehicle-controlled study. Participants having diabetes and noninfected, full-thickness, neuropathic, grade I or II (Wagner classification) DFU, area 1.5–10 cm2, and unresponsive to standard wound care (at least 4 weeks) were randomized to receive topical Galnobax 14% twice daily (BID), Galnobax 20% BID, Galnobax 20% once daily (OD) vehicle, or …
